abiraterone.md

Abiraterone

Zytiga 250mg

臨採

TAH Drug Code	OZYT
Indications	Prostate cancer: Treatment of metastatic, castration-resistant prostate cancer (in combination with prednisone).
Dosing	[Metastatic castration-resistant prostate cancer] 1000 mg orally once daily with prednisone 5 mg orally twice daily.[Metastatic castration-sensitive prostate cancer] 1000 mg orally once daily with prednisone 5 mg orally once daily.Patients receiving ZYTIGA should also receive a gonadotropin-releasinghormone (GnRH) analog concurrently or should have had bilateral orchiectomy. ZYTIGA must be taken on an empty stomach with water at least 1 hour before or 2 hours after a meal. Do not crush or chew tablets.
Hepatic Impairment	Dose adjustment required
Renal Impairment	Dose adjustment not necessary
Contraindications	Hypersensitivity. Pregnancy.
Adverse Effects	Common: Contusion (13.3%), Flushing (15-22.3%), Hypercholesterolemia (Greater than 20%), Hyperglycemia (56.6%), Hypertriglyceridemia (62.5%), Hypophosphatemia (23.8%), Diarrhea (17.6-21.6%), Vomiting (10% or higher), Anemia (Greater than 20%), Lymphocytopenia, All Grades (38.2%), Alkaline phosphatase above reference range (Greater than 20%), Joint swelling (29.5-30.3%), Urinary tract infectious disease (7-11.5%), Cough (6.5-17.3%), Dyspnea (11.8%), Fatigue (39.1%) Serious: Cardiac dysrhythmia (7.2%), Cardiorespiratory arrest (0.5%), Chest discomfort, Chest pain, Edema (25.1-26.7%), Heart failure (2.3-2.6%), Hypertension (8.5-37%), Myocardial infarction, Sudden cardiac death, Torsades de pointes, Adrenal insufficiency (0.5%), Hypoglycemia, Hypokalemia (17.2-28.3%), Lymphocytopenia, Grade 3 or 4 (8.7%), ALT/SGPT level raised (11.1-41.9%), Aspartate aminotransferase serum level above reference range (16-37.3%), Hepatotoxicity, Serum bilirubin above reference range (6.6%)
Pregnancy	Contraindicated
Lactation	Contraindicated
More Info	UpToDate